Director & 10% Owner Ali Behbahani Reports $184M Stock Acquisition, Including $15M Open Market Buy

summarizeSummary

Director and 10% Owner Ali Behbahani acquired $183.99 million in SpyGlass Pharma common stock, including a $15 million open market purchase, as part of a broader insider buying trend post-IPO.

check_boxKey Events

• Significant Open Market Purchase

  Ali Behbahani, a Director and 10% Owner, made a direct open market purchase of 937,500 shares of common stock for $15,000,000 at a price of $16.00 per share on February 9, 2026.

• Automatic Preferred Stock Conversion

  The filing also reports the automatic conversion of approximately $169 million worth of preferred stock into 6,454,801 shares of common stock, a pre-IPO mechanical event that significantly increased the insider's common stock holdings.

• Part of Broader Insider Accumulation

  This transaction is one of several significant insider purchases reported this week, contributing to a net accumulation of over $84 million by 8 active insiders, signaling strong collective confidence in SpyGlass Pharma post-IPO.

auto_awesomeAnalysis

This Form 4 filing indicates a substantial increase in holdings by Ali Behbahani, a Director and 10% Owner, totaling approximately $184 million. The majority of this increase stems from the automatic conversion of preferred stock into common stock, a mechanical event preceding the company's initial public offering. Crucially, the filing also reveals a significant $15 million open market purchase of common stock at $16.00 per share. This discretionary purchase, alongside similar large buys from multiple other insiders this week, signals strong post-IPO confidence and a concerted accumulation trend among key stakeholders. Investors should view this as a strong vote of confidence from a well-informed insider, especially given the cluster of buying activity.